CERTIVOS VERIFIED
Analycor Laboratories
Independent Analysis
- Purity
- 99.2%
- Method
- HPLC + LC-MS
- Tested
- 2026-10-19
F6765KZJRRWX
In Stock
1
$144.99 CAD10,875 successful visitors
No crypto required. Pay with Visa, Mastercard, Amex, Apple Pay, Google Pay, or Interac.
For in vitro laboratory research use only. Not for human consumption. All products are supplied strictly for in vitro laboratory research use only. Not drugs, foods, supplements, or cosmetics. Not evaluated by Health Canada or the FDA.
Dose per Vial
30mg
Sold As
Single vial
Form
Lyophilized powder
Storage
2–8°C
Price
$144.99 CAD
Dual GIP/GLP-1 receptor agonist. 30mg lyophilized powder per vial.
VERIFICATION — Batch CP-032-20260619
All compounds independently tested and verifiedLab results →
Research
Tirzepatide
What It Is
Tirzepatide is a dual-action compound that hits two receptors instead of one — both GIP and GLP-1. Think of it as semaglutide's bigger sibling. Developed by Eli Lilly, it consistently outperforms single-receptor GLP-1 drugs in head-to-head trials. The dual mechanism is why the weight loss numbers are higher.
How It Works
Your gut produces two main "fullness" hormones: GLP-1 and GIP. Semaglutide targets one. Tirzepatide targets both simultaneously. GLP-1 suppresses appetite and slows digestion. GIP influences how your body handles fat and may improve how fat cells respond to insulin. Together, the effect on appetite and metabolism is amplified beyond what either pathway achieves alone.
What The Research Shows
01
SURMOUNT-1 trial: average weight loss of 21% at the highest dose over 72 weeks — roughly 50 lbs for a 240 lb person.
02
In a direct comparison (SURMOUNT-5), tirzepatide beat semaglutide 2.4mg for weight loss. That's the first time anything outperformed sema in a head-to-head.
03
Blood sugar reductions of 2.0–2.6% HbA1c — stronger than any GLP-1 drug tested before it.
04
Also showed significant improvements in liver fat, which matters for anyone concerned about fatty liver.
Sources
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM et al. — N Engl J Med, 2022 · PubMed
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne LJ et al. — N Engl J Med, 2025 · PubMed
Information derived from published preclinical and clinical research. Provided for educational purposes only — not medical advice.
Customer Reviews
- Ryan K.★★★★★
Customer service is top notch and fast delivery!
- Jamie★★★★★
Had my order confirmation instantly, shipping information within hours and product delivered in 2 business days.
- Jessica T.★★★★★
Great communication when a product came back in stock and even got a free bottle of bac water!
- Sanjiv R.★★★★★
Product quality is the best and had it delivered to my office within 72 hours of ordering.